Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drugs Today (Barc). 2007 Jun;43(6):423-31.

Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.

Author information

  • 1Department of General Psychiatry, Innsbruck Medical University, Innsbruck, Austria.

Abstract

Alzheimer's disease is a chronic progressive neurodegenerative disease and it is the most prevalent type of dementia. Diagnostic means, including neuroimaging methods, are continuously improving. Nevertheless, it is still a challenge to increase the sensitivity and specificity of a diagnosis of Alzheimer's disease. Two diagnostic areas are especially challenging: first, differentiating early stages of Alzheimer's disease from mild cognitive impairment and normal aging; and second, increasing diagnostic specificity especially when similar clinical symptoms are shared by various types of dementia. To date, the analysis of beta-amyloid(1-42), total tau and phospho-tau-181 from cerebrospinal fluid (CSF) are the best biological markers to diagnose Alzheimer's disease and differentiate it from other forms of dementia with a high reliability and validity. This article reviews the use of CSF biomarkers and of putative blood-related markers.

PMID:
17612711
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Prous Science
    Loading ...
    Write to the Help Desk